Almirall Launches Act4Impact – its Updated Sustainability Strategy Setting Ambitious Targets for 2030
July 02 2024 - 7:52AM
Business Wire
- Almirall’s sustainability strategy focuses on five pillars:
Planet, People, Patients, Partners and Principles defining clear
targets and measurements
- Among other commitments, Almirall aims to – by 2030 - reduce
absolute direct greenhouse gas emissions by 50%, minimize the
gender pay gap and extend its patient-centric approach
- Almirall’s sustainability achievements have been recognized
by globally leading organizations, including CDP, Ecovadis, and
Sustainalytics, which recently placed the company in the top 5% of
the pharmaceutical industry
Almirall S.A. (BME: ALM), a global pharmaceutical company
dedicated to medical dermatology, launched its new
sustainability strategy Act4Impact 2030 today. The updated
strategy aims at transforming the company’s sustainability roadmap
and focuses on five main pillars: "Planet", "People", "Patients"
"Partners" and “Principles”. Act4Impact consists of 20 strategic
lines of action which will be monitored over time to assess
progress. These include the deployment of its Net Zero Roadmap
through energy decarbonization, sustainable mobility or
supplier engagement plan, as well as the definition and
deployment of the 2030 Global Diversity, Equity, and Inclusion
Plan, including all types of diversity, or the enhancement of our
Supplier Risk Management Process. This comprehensive approach is
aligned with Almirall’s long-term view on its impact on
patients, the medical community, and society and its core
principles of transparency, responsibility, ethics, and
compliance.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240702917901/en/
Almirall photovoltaic installation in HQ
Barcelona (Photo: Business Wire)
Within the Planet pillar of its Act4Impact strategy,
Almirall is committed to taking decisive climate action to become a
net-zero emissions company by 2050. A near-term milestone on
the journey to achieving this goal, is the reduction of emissions
by 50% from its own operations and by 28% from its value chain by
2030. Initiatives to achieve these science-based goals include
energy decarbonization, sustainable mobility and sustainable
procurement practices as well as water stewardship, circular
economy principles, and nature preservation which are aimed at
reducing water usage and waste-to-landfill in the short term.
Through the People pillar, Almirall will prioritize the
implementation of a dedicated program for Diversity, Equity, and
Inclusion, accelerating the achievement of its equity-related
targets, such as the gender pay gap, and measures of employee
perceptions of diversity, equity, and inclusion. To further unlock
talent potential, Almirall is reinforcing its corporate wellbeing
initiatives, and will launch a new social action and volunteering
program.
The patient engagement at Almirall will be further strengthened
within the activities of the Patients pillar focused on
continued engagement with patient organizations, and by further
embedding a patient-centric mindset across the organisation. The
overarching goal is to positively impact over 1.8 million people
through Almirall’s dermatology portfolio by 2030.
Through the “Partners” strategy pillar, by 2030 Almirall
aims for a minimum reduction in CO2 emissions of 69% among
suppliers with a carbon scorecard. The company will roll out
sustainable procurement programs and engage suppliers in its Net
Zero Supplier Engagement initiative.
Throughout these endeavours, Almirall remains committed to
fostering an ethical and transparent corporate culture, emphasizing
accountability and adherence to best performance Principles,
which is the fifth pillar of the strategy. To this end, the company
is planning to provide sustainability training to all employees by
2030 and will gauge employee perceptions on the company
culture.
Almirall's CEO and President, Carlos Gallardo, emphasized
that "in line with our long-term vision, and our commitment to
patients, the medical community, and society, our updated
sustainability strategy is a key element of our business strategy.
Our Act4Impact strategy is at the heart of our decision making and
aligned with our purpose to transform the lives of patients”.
Almirall has been committed to conducting its operations in a
responsible and sustainable manner for many years. These efforts
have resulted in a number of recognitions and awards for the
company. Recently, the Almirall was rated by Sustainalytics,
amongst the top 5% of companies in the pharmaceutical
industry. CDP (Carbon Disclosure Project) awarded Almirall
an outstanding "A-, Leadership" score in Climate Change and a "B,
Management" score in Water Security. Ecovadis recognized
Almirall with a platinum medal, placing it in the top 1% of
evaluated pharmaceutical companies for sustainability.
About Almirall
Almirall is a global pharmaceutical company dedicated to medical
dermatology. We closely collaborate with leading scientists,
healthcare professionals, and patients to deliver our purpose: to
transform the patients' world by helping them realize their hopes
and dreams for a healthy life. We are at the forefront of science
to deliver ground-breaking, differentiated medical dermatology
innovations that address patients´ needs.
Almirall, founded in 1944 and headquartered in Barcelona, is
publicly traded on the Spanish Stock Exchange (ticker: ALM, total
revenue in 2023: €898.8 MM, 1900 employees globally). Almirall
products help to improve the lives of patient every day and are
available in over 100 countries.
For more information, please visit
https://www.almirall.com/
Legal warning
This document includes only summary information and is not
intended to be exhaustive. The facts, figures and opinions
contained in this document, in addition to the historical ones, are
"forward-looking statements". These statements are based on the
information currently available and the best estimates and
assumptions that the company considers reasonable. These statements
involve risks and uncertainties beyond the control of the company.
Therefore, actual results may differ materially from those declared
by such forward-looking statements. The company expressly waives
any obligation to revise or update any forward-looking statements,
goals or estimates contained in this document to reflect any
changes in the assumptions, events or circumstances on which such
forward-looking statements are based, unless required by the
applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240702917901/en/
Corporate Communications:
corporate.communication@almirall.com Phone: (+34) 659 614
173
Investor Relations investors@almirall.com
Phone: (+34) 93 291 30 87